AngioDynamics (NSDQ:ANGO) won FDA clearance for its BioFlo peripherally-inserted central catheters, the company announced this week.

BioFlo is AngioDynamics’ 1st device to include the proprietary Endexo technology for reducing the accumulation of blood clots on and in the catheter, according to a press release.

The Albany, N.Y.-based device maker plans to initiate commercial launch in the U.S. within the next 30 days.

The BioFlo catheter, which already has CE Mark approval in the European Union as well as regulatory approval in Canada and other international markets, demonstrated an average 87% reduction in thrombus accumulation on its surface when compared to other commonly used devices, according to AngioDynamics.

"BioFlo technology provides AngioDynamics with a truly disruptive technology which we believe will drive increased demand for our vascular access products," president & CEO Joseph DeVivo said in prepared remarks. "With 15% of the $375 million U.S. PICC market, AngioDynamics holds a strong second position and BioFlo technology is positioned to help us grow that presence."